ChenGuang Biotech Group Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Qingguo Lu

İcra Kurulu Başkanı

CN¥2.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	21.3%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

Oct 08

ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Sep 30

Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

May 13

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

CEO

Qingguo Lu (65 yo)

no data

Görev süresi

CN¥2,118,500

Tazminat

Mr. Qingguo Lu is Chairman & GM of ChenGuang Biotech Group Co., Ltd.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qingguo Lu	Chairman & GM	no data	CN¥2.12m	21.3% CN¥ 875.7m
Jing Zhou	CFO, Secretary of the Board & Director	5.6yrs	CN¥678.00k	1.71% CN¥ 70.4m
Tao Zhao	Employee Representative Supervisor	no data	Veri yok	0.011% CN¥ 450.6k
Ying Lu	Non-Independent Director	1.5yrs	CN¥3.97m	Veri yok
Wei Gao	Supervisory Board Chairman	no data	CN¥652.40k	0.015% CN¥ 631.5k
Shaohua Wang	Non Employee Representative Supervisor	no data	Veri yok	Veri yok
Xiaofeng Dai	Independent Director	1.5yrs	CN¥49.00k	Veri yok
Hong Niu	Independent Director	1.5yrs	CN¥49.00k	Veri yok
Liangqiu Li	Independent Director	1.5yrs	CN¥49.00k	Veri yok

1.5yrs

Ortalama Görev Süresi

44yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300138 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

ChenGuang Biotech Group Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.19 profit in 3Q 2023)

Investor sentiment improves as stock rises 15%

A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 19%

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.31 in 2Q 2023)

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend on A Shares for the Year 2023, Payable on 13 June 2024

Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend for the Year 2023

Price target decreased by 7.3% to CN¥17.31

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

ChenGuang Biotech Group Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: CN¥0.91 (vs CN¥0.81 in FY 2022)

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on November 17, 2023.

Price target decreased by 8.0% to CN¥20.43

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

ChenGuang Biotech Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 17 May 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.82 (vs CN¥0.67 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Chenguang Biotech Group Co., Ltd. Announces 2021 Final Cash Dividend Proposal on A Shares, Payable on 1 June 2022

Consensus revenue estimates increase by 11%

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chenguang Biotech Group Co., Ltd. Approves Cash Dividend

Full year 2021 earnings: EPS and revenues exceed analyst expectations

ChenGuang Biotech Group Co., Ltd. Announces Final Dividend For the Year 2021

Price target increased to CN¥20.80

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Revenue and earnings beat expectations

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥15.29

Investor sentiment deteriorated over the past week

New 90-day high: CN¥19.53

Market bids up stock over the past week

New 90-day high: CN¥18.18

Third quarter earnings released

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) agreed to acquire an additional 24.83% stake in Xinjiang Tianjiao Hongan Agricultural Technology Co., Ltd. from Xinjiang Longping Gaoke Hong'an Seed Industry Co., Ltd. for CNY 20 million.

Earnings released

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥16.99

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) cancelled the acquisition of 10% stake in Tengchong Kang’enpu Biological Materials Co., Ltd. from Zhu Jingbo, Chen Xin and Zhang Jiaqi.

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi